We are pioneering a new class of drugs that activate the immune system to recognize cancer cells as foreign invaders, helping the patients mount a natural anti-tumor response.
Our therapeutics, target the tumor microenvironment of cancer cells, recruiting and amplifying the patient’s own immune system to fight cancer.
The biological and biophysical properties of the tumor microenvironment are unlike other parts of the body, presenting unique challenges.
We are developing a broad pipeline of differentiated, drug molecules with novel and complementary mechanisms of action.
Our drugs have the potential to become breakthrough therapies in many hard-to-treat cancers and increase the success rates of cancer treatment.
Conformation-X is developing a comprehensive pipeline of innovative first-in-class biologics as well as orally available, small molecule drugs that target immune checkpoints.
Conformation-X is developing a comprehensive pipeline


Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline
CANTON, Mass.–(BUSINESS WIRE)–Conformation-X Therapeutics, LLC, an immune-oncology focused drug development company, announced today that it has closed an oversubscribed funding tranche of $3.65M, bringing the total raised since inception to over $13.5M. The company unveiled its lead assets by disclosing successful ex vivo and in vivo proof-of-concept studies for its HHLA2 and IL18BP programs, marking critical milestones in the cancer drug development process.


45 Dan Rd., Ste. 382
Canton, MA 02021 USA
+1 339-502-8630